HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida

NRx Pharmaceuticals announced that its subsidiary, HOPE Therapeutics, has initiated patient care using the Ampa one-day protocol for treatment-resistant depression, marking the first deployment of its kind in Florida and among the first nationwide. The innovative approach combines a single day of transcranial magnetic stimulation with physician-prescribed D-cycloserine and lisdexamfetamine, representing a significant advancement in depression treatment methodology.

Peer-reviewed studies have demonstrated remarkable outcomes with this protocol, showing response rates of 87% and remission rates of 72% in nonrandomized trials. These results substantially exceed traditional depression treatment outcomes, particularly for patients who have not responded to conventional therapies. The protocol's effectiveness in treating both depression and PTSD positions it as a potential breakthrough in mental health care.

Under the direction of Medical Director Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering the revolutionary treatment approach. Dr. Cohen emphasized that the results have the potential to change the paradigm of TMS therapy from months-long regimens to a rapid, one-day approach that may transform care for millions battling depression and PTSD. The company expects to expand to six Florida locations by year-end, significantly increasing access to this innovative treatment.

The traditional TMS treatment typically requires daily sessions over several weeks or months, creating significant barriers for patients who must balance treatment with work, family responsibilities, and transportation challenges. The one-day protocol addresses these practical concerns while delivering superior clinical outcomes. This development comes at a critical time when mental health needs are increasing nationwide, and innovative solutions are urgently needed.

NRx Pharmaceuticals continues to advance its NMDA platform for central nervous system disorders, with additional therapeutics in development for suicidal depression, chronic pain, and PTSD. The successful implementation of the one-day TMS protocol in Florida represents a major milestone in making advanced mental health treatments more accessible and effective for patients who have exhausted conventional options. For more information about the company's developments, visit https://www.newmediawire.com.